Iterum Therapeutics PLC

NASDAQ ITRM

Download Data

Iterum Therapeutics PLC Price to Sales Ratio (P/S) on June 03, 2024: 9.04

Iterum Therapeutics PLC Price to Sales Ratio (P/S) is 9.04 on June 03, 2024, a NA change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.
  • Iterum Therapeutics PLC 52-week high Price to Sales Ratio (P/S) is 10.17 on May 09, 2024, which is 12.59% above the current Price to Sales Ratio (P/S).
  • Iterum Therapeutics PLC 52-week low Price to Sales Ratio (P/S) is 8.15 on May 30, 2024, which is -9.79% below the current Price to Sales Ratio (P/S).
  • Iterum Therapeutics PLC average Price to Sales Ratio (P/S) for the last 52 weeks is 9.06.
NASDAQ: ITRM

Iterum Therapeutics PLC

CEO Mr. Corey N. Fishman
IPO Date May 25, 2018
Location Ireland
Headquarters Fitzwilliam Court, Dublin, Ireland, 2
Employees 14
Sector Healthcare
Industry Biotechnology
Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Similar companies

HOTH

Hoth Therapeutics Inc

USD 1.17

0.00%

StockViz Staff

September 8, 2024

Any question? Send us an email